SS
TELO icon

SBI Securities’s Telomir Pharmaceuticals TELO Stock Holding History

SBI Securities’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5 Hold
4
– – ﹤0.01% 3995
2026
Q1 		$5 Hold
4
– – ﹤0.01% 3920
2025
Q4 		$5 Hold
4
– – ﹤0.01% 3936
2025
Q3 		$6 Hold
4
– – ﹤0.01% 4098
2025
Q2 		$5 Buy
4
+1
+33% +$2 ﹤0.01% 4075
2025
Q1 		$10 Hold
3
– – ﹤0.01% 3971
2024
Q4 		$12 Buy
+3
New +$14 ﹤0.01% 3913

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

SBI Securities's TELO Position: Q2 2026 in Review

SBI Securities held its Telomir Pharmaceuticals (TELO) position steady in Q2 2026 at 4 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #3995.

SBI Securities first reported a position in TELO in Q4 2024 and has held it in 7 quarters since. The position peaked at $12 in Q4 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • SBI Securities held 4 shares of Telomir Pharmaceuticals worth $5 as of Q2 2026.
  • SBI Securities left its Telomir Pharmaceuticals share count unchanged in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3995 holding.
  • SBI Securities first reported a position in Telomir Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Telomir Pharmaceuticals position peaked at $12 in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.